ES2180643T3 - Procedimiento para tratar la disfuncion cognitiva. - Google Patents

Procedimiento para tratar la disfuncion cognitiva.

Info

Publication number
ES2180643T3
ES2180643T3 ES95922148T ES95922148T ES2180643T3 ES 2180643 T3 ES2180643 T3 ES 2180643T3 ES 95922148 T ES95922148 T ES 95922148T ES 95922148 T ES95922148 T ES 95922148T ES 2180643 T3 ES2180643 T3 ES 2180643T3
Authority
ES
Spain
Prior art keywords
procedure
cognitive dysfunction
treat cognitive
treat
dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95922148T
Other languages
English (en)
Inventor
Charles M Beasley Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority claimed from CA002219902A external-priority patent/CA2219902A1/en
Application granted granted Critical
Publication of ES2180643T3 publication Critical patent/ES2180643T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Light Receiving Elements (AREA)
  • Processing Of Meat And Fish (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION PROPORCIONA UN METODO PARA TRATAR UNA DISFUNCION COGNITIVA QUE COMPRENDE LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE 2
ES95922148T 1995-05-30 1995-05-30 Procedimiento para tratar la disfuncion cognitiva. Expired - Lifetime ES2180643T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1995/006859 WO1996038151A1 (en) 1995-05-30 1995-05-30 Method for treating cognitive dysfunction
CA002219902A CA2219902A1 (en) 1995-05-30 1995-05-30 Use of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine for treating cognitive dysfunction

Publications (1)

Publication Number Publication Date
ES2180643T3 true ES2180643T3 (es) 2003-02-16

Family

ID=25679786

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95922148T Expired - Lifetime ES2180643T3 (es) 1995-05-30 1995-05-30 Procedimiento para tratar la disfuncion cognitiva.

Country Status (16)

Country Link
EP (1) EP0828494B1 (es)
JP (1) JPH11506096A (es)
AT (1) ATE220550T1 (es)
AU (1) AU707858B2 (es)
CZ (1) CZ292565B6 (es)
DE (1) DE69527442T2 (es)
DK (1) DK0828494T3 (es)
ES (1) ES2180643T3 (es)
FI (1) FI973987A0 (es)
HU (1) HUT77907A (es)
MX (1) MX9707936A (es)
NO (1) NO318553B1 (es)
NZ (1) NZ288037A (es)
PL (1) PL189714B1 (es)
PT (1) PT828494E (es)
WO (1) WO1996038151A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
SI1838716T1 (sl) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270464A (en) * 1989-03-14 1993-12-14 Janssen Pharmaceutica N.V. Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
DE69527442D1 (de) 2002-08-22
PL189714B1 (pl) 2005-09-30
JPH11506096A (ja) 1999-06-02
NO974766L (no) 1997-12-09
PT828494E (pt) 2002-10-31
HUT77907A (hu) 1998-10-28
PL323785A1 (en) 1998-04-27
EP0828494A1 (en) 1998-03-18
MX9707936A (es) 1997-12-31
AU2693695A (en) 1996-12-18
FI973987L (fi) 1997-10-17
AU707858B2 (en) 1999-07-22
DE69527442T2 (de) 2003-02-20
CZ324397A3 (cs) 1998-08-12
HK1009393A1 (en) 1999-06-04
NO318553B1 (no) 2005-04-11
FI973987A7 (fi) 1997-10-17
EP0828494A4 (en) 1999-11-24
DK0828494T3 (da) 2002-09-02
CZ292565B6 (cs) 2003-10-15
EP0828494B1 (en) 2002-07-17
NO974766D0 (no) 1997-10-15
FI973987A0 (fi) 1997-10-17
WO1996038151A1 (en) 1996-12-05
ATE220550T1 (de) 2002-08-15
NZ288037A (en) 1999-09-29

Similar Documents

Publication Publication Date Title
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
GB9514451D0 (en) Sustained-release formulation
ATE220896T1 (de) Hydrogelformulierung mit gesteuerter freisetzung
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
ES2164842T3 (es) Procedimiento para la preparacion de composiciones de microcapsulas.
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
ZA9711279B (en) Method for treating and preventing neurological disorders and promoting wound healing.
MX9401294A (es) Derivados de azolona sustituida
ES2168766T3 (es) Preparacion farmaceutica que incluye el propeptido vwf.
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
BR9713522A (pt) Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
ATE206915T1 (de) Behandlung von angstzuständen
ES2180643T3 (es) Procedimiento para tratar la disfuncion cognitiva.
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
DE69736180D1 (de) Behandlung von manischen erkrankungen
NO982582L (no) Fremgangsmaate for behandling av smerte
SE9403160D0 (sv) Method and means for prevention and treatment of secondary cataract
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa
BR9612549A (pt) Método para tratamento de agressão excessiva
ES2120573T3 (es) 24-epi-1-alfa-hidroxivitamina d2 para tratar la osteoporosis.
AR010987A1 (es) Composicion farmaceutica y metodo para tratar un trastorno compulsivo.
EA199800818A1 (ru) Способ лечения бессонницы